ALK translocation is a rarer entity, detected in only 3–7% of NSCLC patients [28]; however, among these patients, synchronous BM diagnosis or CNS progression within months of diagnosis is reportedly as high as 25–40% [1,29]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.